Wang, J.-S.; Tsai, P.-H.; Tseng, K.-F.; Lin, C.-L.; Chen, F.-Y.; Chang, C.-T.; Shen, M.-Y.
Long-Term Pentoxifylline Therapy Is Associated with a Reduced Risk of Atherosclerotic Cardiovascular Disease by Inhibiting Oxidative Stress and Cell Apoptosis in Diabetic Kidney Disease Patients. Antioxidants 2024, 13, 1471.
https://doi.org/10.3390/antiox13121471
AMA Style
Wang J-S, Tsai P-H, Tseng K-F, Lin C-L, Chen F-Y, Chang C-T, Shen M-Y.
Long-Term Pentoxifylline Therapy Is Associated with a Reduced Risk of Atherosclerotic Cardiovascular Disease by Inhibiting Oxidative Stress and Cell Apoptosis in Diabetic Kidney Disease Patients. Antioxidants. 2024; 13(12):1471.
https://doi.org/10.3390/antiox13121471
Chicago/Turabian Style
Wang, Jie-Sian, Ping-Hsuan Tsai, Kuo-Feng Tseng, Cheng-Li Lin, Fang-Yu Chen, Chiz-Tzung Chang, and Ming-Yi Shen.
2024. "Long-Term Pentoxifylline Therapy Is Associated with a Reduced Risk of Atherosclerotic Cardiovascular Disease by Inhibiting Oxidative Stress and Cell Apoptosis in Diabetic Kidney Disease Patients" Antioxidants 13, no. 12: 1471.
https://doi.org/10.3390/antiox13121471
APA Style
Wang, J.-S., Tsai, P.-H., Tseng, K.-F., Lin, C.-L., Chen, F.-Y., Chang, C.-T., & Shen, M.-Y.
(2024). Long-Term Pentoxifylline Therapy Is Associated with a Reduced Risk of Atherosclerotic Cardiovascular Disease by Inhibiting Oxidative Stress and Cell Apoptosis in Diabetic Kidney Disease Patients. Antioxidants, 13(12), 1471.
https://doi.org/10.3390/antiox13121471
